PCOS isnt on the MHRA-licensed list for Mounjaro or Wegovy, even though its a weight-related condition with strong evidence for GLP-1 benefit
Looking ahead, the future of PDCs involves the development of PDCs based on humanized antibodies, 129 exploring stimuli-responsive drug release mechanisms, 130 employing computer-aided drug design, 131 exploring diverse receptors or antigens, 132 integrating with immunotherapies and gene therapies to address stability, off-target effects and resistance issues, 133,134 and advancing scalable manufacturing processes
The 30-minute post-dose window applies before other medicines, which is relevant for patients taking morning medication or drugs with a narrow therapeutic window
So we are probably less exposed than most of the industry, I would say. Look at the way companies are starting to have to defend themselves and explain their business
As individuals vary so will results from using this product